

For Immediate Release

Q1 Net Revenue at Rs 648 Crores, Net Profit at Rs 65 Crores

Vadodara July 20th, 2017

Alembic Pharmaceuticals Limited reported its consolidated financial results for the first quarter ending 30th June 2017.

Financial Highlights

- Net Sales for the quarter at Rs 648 crores against Rs 737 crores last year.
- Net Profit for the quarter at Rs 65 crores against Rs 102 crores last year.

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said "The performance in the quarter was weak primarily due to the transitional provision of GST on the India Branded business. Our expansion is progressing well and our Oncology facility was recently inaugurated by the Honorable Chief Minister of Gujarat, Shri Vijaybhai Rupani"

Operational Highlights for the quarter

International Business

- International formulation business revenue was Rs 282 crores against Rs 309 crores last year
- US formulation business revenue was Rs 211 crores for the quarter
- 6 ANDA approvals received during the quarter, Cumulative ANDA approvals at 58
- 6 ANDA filings during the quarter, Cumulative ANDA filings at 101
- R&D spend at Rs 94 Crores, approximately 14% of Sales.

India Formulations Business

- India formulations business for the quarter at Rs 236 crores as against Rs 299 crores last year



ALEMBIC PHARMACEUTICALS LIMITED

Summary of Total Revenue is as under:
(Rs in Crores)

Particulars	Q1 FY18	Q1 FY17
Formulation		
International	282	309
India	236	299
API	130	129
Total	648	737

The Profit break-up is as under:
(Rs in Crores)

Particulars	Q1 FY18	Q1 FY17
EBITDA Pre R&D	195	237
<i>EBITDA Pre R&D %</i>	<i>30%</i>	<i>32%</i>
EBITDA Post R&D	105	157
<i>EBITDA Post R&D %</i>	<i>16%</i>	<i>21%</i>
Profit Before Tax	79	137
Net Profit after Tax	65	102



ALEMBIC PHARMACEUTICALS LIMITED

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembicpharmaceuticals.com;
(reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Ajay Kumar Desai	Mitanshu Shah
Phone: +91 22 – 306 11681	Phone: +91 265 – 3007630
Email: ajay.desai@alembic.co.in	Email: mitanshu.shah@alembic.co.in



ALEMBIC PHARMACEUTICALS LIMITED